Waning of SARS-CoV-2 Antibody levels response to inactivated cellular vaccine over 6 months among healthcare workers
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Background
Health Care workers (HCW) are an important group affected by this pandemic and COVID-19 has presented substantial challenges for health professionals and health systems in many countries. The Brazilian vaccination plan implemented in October, so that third dose for HCW. However, the persistence of CoronaVac vaccine-induced immunity is unknown, and immunogenicity according to age cohorts may differ among individuals.
Objective
Evaluate the post vaccination immune humoral response and the relationship between post-vaccination seropositivity rates and demographic data among Healthcare Workers over 6 months after CoronaVac immunization.
Methods
A cross section study including Healthcare professionals vaccinated with CoronaVac for 6 months or more. The study was carried with the analysis of post-vaccination serological test to assess the levels of humoral response after vaccination.
Results
329 participants were included. Among them, 76% were female. Overall, 18.5% were positive quantitative titles (IQR 42.87-125.5) and the negative group was 80%, quantitative titles (IQR 5.50-13.92).
Conclusion
It was possible to identify a group with positive quantitative titles in serological test for IgG antibody against the SARS-CoV-2. Further investigation is required to determine the durability of post-vaccination antibodies and how serological tests can be determine the ideal timing of vaccine booster doses.
Article activity feed
-
SciScore for 10.1101/2021.12.30.21268532: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: The study was approved by the Ethics Committee of the Federal University of São Paulo (CAE-47617621.6.0000.5505).
Consent: All participants signed an informed consent form and participated in the study.Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources IgG antibody assays against SARS-CoV-2 RBD protein were performed using the Access SARS-CoV-2 IgG antibody (1°IS) (Beckman Coulter, Inc.) according to the manufacturer’s instructions. SARS-CoV-2 IgGsuggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share …
SciScore for 10.1101/2021.12.30.21268532: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: The study was approved by the Ethics Committee of the Federal University of São Paulo (CAE-47617621.6.0000.5505).
Consent: All participants signed an informed consent form and participated in the study.Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources IgG antibody assays against SARS-CoV-2 RBD protein were performed using the Access SARS-CoV-2 IgG antibody (1°IS) (Beckman Coulter, Inc.) according to the manufacturer’s instructions. SARS-CoV-2 IgGsuggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:One limitation of this study is the use of an immunochemiluminescence test as a surrogate marker of the immune humoral response, and not a plaque reduction neutralization test. Nonetheless, the assay detected the total immunodominant neutralizing antibodies that targeted the viral peak protein (S) receptor binding domain (RBD). It is generally used as a test of high sensitivity and specificity, and is evaluated as a correlate of protection in the recent studies cited above. Indeed, a previous study on IgG antibody tests and their correlation with the SARS-CoV-2 surrogate virus neutralization test (sVNT) in patients with COVID-19 has been evaluated and validated by analyzing convalescent serum and samples from non-COVID-19 patients. (13) Other immunological markers not tested in our study may contribute to the protection of previously immunized patients, even in the absence of antibody persistence. A non-peer-reviewed study of Brazilian professional health workers reported a 50.7% efficacy of CoronaVac in the prevention of severe forms of SARS-CoV-2 infections in a phase 3 clinical trial. (14) Another study published in China showed that HCW maintained their B cells and T cells specific for SARS-CoV-2 detection five months after two doses of the Sinopharm vaccine. (15)
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
